Summit Therapeutics (SMMT) Net Cash Flow (2020 - 2026)

Summit Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$118.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 211.36% year-over-year to -$118.7 million; the trailing twelve-month figure through Mar 2026 stood at -$105.1 million (down 169.96% YoY), and the FY2025 full-year result was $120.3 million, up 256.11% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$118.7 million, down from -$13.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $525.3 million in Q4 2022, with the low at -$578.1 million in Q1 2023.
• Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of -$9.8 million in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow jumped 6634.72% — and 2023, when it sank 10024.15%.
• Summit Therapeutics' Net Cash Flow stood at $525.3 million in 2022, then tumbled by 90.98% to $47.4 million in 2023, then tumbled by 76.36% to $11.2 million in 2024, then sank by 218.55% to -$13.3 million in 2025, then plunged by 794.47% to -$118.7 million in 2026.
• The last three Net Cash Flow figures came in at -$118.7 million (Q1 2026), -$13.3 million (Q4 2025), and -$59.3 million (Q3 2025), per Business Quant data.